Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial

• Principais autores: Jialin Yao (Autor), Yan Lu (Autor), Lijing Jiao (Autor), Ling Bi (Autor), Wenxiao Yang (Autor), Lingzi Su (Autor), Jun Shi (Autor), Zhe Wang (Autor), Yabin Gong (Autor), Ling Xu (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the prognosis of non-small cell lung cancer (NSCLC) with EGFR mutation-positive. Although third-generation EGFR-TKI osimertinib is demonstrated with superior efficacy compared with first-...